MPNs: CML, PV, ET, PMF, CEL Flashcards
Which MPN has the longest survival and lowest transformation (5%) to Acute Leukemia?
Essential Thrombocythemia (ET)
What is the Diagnostic Criteria for ET? (4)
Aimed at excluding secondary thrombocytosis and other MPNs
- Sustained Thrombocytosis (>450)
- BM w/ Megakaryocytic Hyperplasia w/O panmyelosis (no significant increase in granulocytic/erythroid precursors)
- Fails to meet criteria for PV, PMF, CML, or MDS
- JAK2 B617F mutation (or no evidence for reactive thromobocytosis)
CML Imatinib Resistance:
-% Initially present
-5% of cases initially (emerges during treatment in many more)
Philadelphia Chromosome:
-Most commonly occurs where and with what?
In major breakpoint cluster (M-BCR)
-w/ p210 fusion protein
Essential Thrombocythemia (ET): -Bone Marrow findings (4)
- Large, Hyperlobated Megs
- Paratrabecular
- Emperipolesis
- Stainable Iron Present
Most common cause of death in PV?
-2nd
Thrombosis
-Acute Leukemia
Mutations in what, produce a small subset of ET and PMF but are NOT seen in PV?
MPL mutations
-MPL W515L or W515K
What is the Philadelphia Chromosome?
Reciprocal Translocation of chromosomes 9 and 22
-t(9;22)(q34;q11)
Primary Myelofibrosis (PMF) - Cellular (Prefibrotic) Stage: -Presentation (3)
- Anemia
- Mild Leukocytosis
- Thrombocytosis
Polycythemia Vera (PV) - Diagnostic Criteria: -General (2)
- Both Major + 1 Minor
- 1st Major + 2 Minor
What is the Jak-2 protein involved in?
Stimulating the STAT pathway
CML Imatinib Resistance:
-Result of what?
Mutations within the BCR-ABL gene
- Tyrosine Kinase Domain
- P-loop (so-called)
CML is defined by the presence of what?
Philadelphia Chromosome
-t(9;22) - BCR/ABL
Essential Thrombocythemia (ET):
- Incidence
- Presentation
- Bimodal (peaks at age 30 and 60)
- Isolated Thrombocytosis
CML - Blast Phase manifests as what types of acute leukemia? (2)
-Percentages
- AML (70%)
- ALL (30%)
CML - Chronic Phase:
-Peripheral Blood (6)
Leukocytosis with: -Neutrophilia -Monocytosis -Basophilia -Eosinophilia Thrombocytosis
What is the most powerful Prognostic Factor in CML?
Response to Tyrosine Kinase Inhibitor (TKI) therapy as measured by Quantitative RT-PCR.
Chronic Eosinophilic Leukemia (CEL):
-Must exclude other hematolymphoid neoplasms w/ eosinophilia (3)
Rearrangements of:
- PDGFRa
- PDGFRb
- FGFR1